Stroke is a major cause of death and disability in the world. There were approximately 25.7 million stroke survivors and 6.5 million deaths from stroke [1]. Stroke can result in arm disability and reduce daily life activity via weak arm muscle activity [2]. Studies have been performed to discover therapeutic and assistive approaches to compensate for disabilities and restore functions. 

Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2), the causative agent of COVID-19 respiratory disease, was first identified on 7 December 2019, and quickly spread worldwide. The SARS-CoV-2 belongs to Coronaviridea family, enveloped single-stranded RNA viruses. The family is divided into two subfamilies, the Coronavirinae and the Torovirinae, distinguished by the shape of their nucleocapsids . Virions are roughly spherical and are notable for the large spike (S) glycoprotein that mediate viral entry to the host cell. The subfamily Coronavirinae consists of four genera, the alpha-, beta-, gamma-, and delta-coronaviruses. There are seven coronaviruses that can infect people – four of them causing a common cold (229E, NL63, OC43, HKU1), and three are associated with potentially severe respiratory conditions, namely severe syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and the emerging type of SARS-CoV-2, which has 79% sequence homology with SARS-CoV.

Introduction: Resolvin D2 (RvD2), a mediator that helps resolve inflammation, plays a role in stopping the progression of atherosclerotic cardiovascular disease (ASCVD). Understanding how RvD2 levels relate to ASCVD risk could reveal its potential as both a treatment target and a biomarker. Methods: We examined the research by Liu et al., which used an analytical method that combined restricted cubic splines with multivariable Cox proportional hazard models.